P/E ratio for uniQure (QURE)
P/E ratio as of May 2024 (TTM): -1.29
According to uniQure's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -1.2868. At the end of 2022 the company had a P/E ratio of -8.37.
P/E ratio history for uniQure from 2014 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -8.37 | -388.39% |
| 2021 | 2.90 | -122.56% |
| 2020 | -12.9 | -44.02% |
| 2019 | -23.0 | 86.49% |
| 2018 | -12.3 | 84.84% |
| 2017 | -6.66 | 248.63% |
| 2016 | -1.91 | -58.04% |
| 2015 | -4.55 | -7.31% |
| 2014 | -4.91 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Amgen AMGN | 22.2 | -1,828.45% | 🇺🇸 USA |
 Sanofi SNY | 15.4 | -1,292.96% | 🇫🇷 France |
 Sangamo Therapeutics
SGMO | -0.4227 | -67.15% | 🇺🇸 USA |
 bluebird bio
BLUE | -1.03 | -20.00% | 🇺🇸 USA |
 BioMarin Pharmaceutical BMRN | 98.8 | -7,781.78% | 🇺🇸 USA |
 Avidity Biosciences RNA | -9.26 | 619.97% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.